Valuation : Viking Therapeutics, Inc.

Market Cap 3.75B 3.23B 3.03B 2.77B 5.2B 357B 5.24B 35.91B 13.96B 181B 14.09B 13.78B 599B P/E 2026 *
-7.11x
P/E 2027 * -7.72x
Enterprise Value 3.31B 2.85B 2.68B 2.45B 4.59B 315B 4.62B 31.7B 12.33B 160B 12.44B 12.17B 529B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.91%
Yield 2026 *
-
Yield 2027 * -
1 day+1.93%
1 week-1.35%
Current month+3.28%
1 month+3.28%
3 months+4.83%
6 months+2.66%
Current year-6.82%
1 week 31.7
Extreme 31.7
34.99
1 month 31.28
Extreme 31.28
36.26
Current year 25.77
Extreme 25.77
42.79
1 year 22.96
Extreme 22.959
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 2012-09-23
Director of Finance/CFO 55 2021-01-03
Chief Tech/Sci/R&D Officer 57 2026-06-10
Director TitleAgeSince
Chairman 68 2015-04-30
Chairman 60 2012-09-23
Director/Board Member 53 2014-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/1/26 Free

Director

47,133 0.0404%
7/29/26 Sell

Chief Operating Officer

-18,217 0.0157%
7/29/26 Sell

Founder

-148,517 0.1279%
Change 5-day change 1-year change 3-year change Capi.($)
+1.93%-1.35%+19.24%+137.36% 3.75B
-1.66%-4.96%+49.84%+88.43% 69.54B
-2.19%+1.32%+44.54%+88.38% 64.97B
-3.57%-4.24%+47.11%+5.60% 26.51B
+2.77%-1.74%-16.16%+456.51% 25.89B
-0.46%-9.94%+0.98%-15.98% 25.64B
-9.71%-0.36%+245.87%+377.68% 20.22B
-1.58%+0.47%+29.35%-19.62% 19.98B
-3.36%-7.58%+9.47%+535.81% 15.69B
+0.35%+0.16%+46.96%+144.04% 13.49B
Average -1.75%-3.84%+47.72%+179.82% 28.57B
Weighted average by Cap. -1.96%-3.52%+47.70%+145.46%

Financials

2026 *2027 *
Net sales - -
Net income -541M -466M -438M -400M -750M -51.5B -755M -5.18B -2.01B -26.12B -2.03B -1.99B -86.48B -539M -464M -436M -398M -747M -51.31B -753M -5.16B -2.01B -26.03B -2.02B -1.98B -86.16B
Net Debt -439M -378M -355M -324M -609M -41.8B -613M -4.2B -1.64B -21.2B -1.65B -1.61B -70.19B -520M -448M -420M -384M -720M -49.46B -725M -4.97B -1.93B -25.09B -1.95B -1.91B -83.04B
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
65
Date Price Change Volume
26-08-31 US$32.78 +1.93% 1,660,226
26-08-28 US$32.16 -5.02% 2,379,840
26-08-27 US$33.86 -1.51% 2,207,014
26-08-26 US$34.38 +0.61% 1,144,995
26-08-25 US$34.17 +2.83% 2,095,969
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
32.78USD
Average target price
92.39USD
Spread / Average Target
+181.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VKTX Stock